Lazard Ltd (LAZ) Reaches $55.61 After 3.00% Down Move; Profile of 5 Analysts Covering Aratana Therapeutics, Inc. (PETX)

February 15, 2018 - By Dolores Ford

Among 8 analysts covering Aratana Therapeutics (NASDAQ:PETX), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Aratana Therapeutics had 18 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Hold” rating by Craig Hallum given on Friday, September 25. The stock of Aratana Therapeutics, Inc. (NASDAQ:PETX) earned “Buy” rating by Lake Street on Wednesday, July 29. The stock has “Buy” rating by Jefferies on Wednesday, November 15. The firm earned “Buy” rating on Friday, August 19 by Jefferies. The stock of Aratana Therapeutics, Inc. (NASDAQ:PETX) earned “Outperform” rating by Credit Suisse on Thursday, February 4. The stock has “Hold” rating by Stifel Nicolaus on Monday, October 23. Stifel Nicolaus maintained it with “Hold” rating and $6.0 target in Monday, December 18 report. The firm has “Hold” rating given on Wednesday, December 27 by C.L. King. The company was maintained on Wednesday, March 16 by Stifel Nicolaus. The firm earned “Buy” rating on Thursday, June 8 by Jefferies. See Aratana Therapeutics, Inc. (NASDAQ:PETX) latest ratings:

16/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $10.0 Maintain
27/12/2017 Broker: C.L. King Rating: Hold Initiate
18/12/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $6.0 Maintain
15/11/2017 Broker: Jefferies Rating: Buy New Target: $8.5 Maintain
17/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $10 Initiates Coverage On
03/11/2017 Broker: Jefferies Rating: Buy New Target: $8.0 Maintain
23/10/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $7.0 Maintain

The stock of Lazard Ltd (NYSE:LAZ) is a huge mover today! The stock decreased 1.54% or $0.87 during the last trading session, reaching $55.61. About 429,333 shares traded. Lazard Ltd (NYSE:LAZ) has risen 35.63% since February 15, 2017 and is uptrending. It has outperformed by 18.93% the S&P500.The move comes after 8 months negative chart setup for the $7.22B company. It was reported on Feb, 15 by Barchart.com. We have $53.94 PT which if reached, will make NYSE:LAZ worth $216.48M less.

The stock increased 0.30% or $0.01 during the last trading session, reaching $4.27. About 109,734 shares traded. Aratana Therapeutics, Inc. (NASDAQ:PETX) has risen 1.52% since February 15, 2017 and is uptrending. It has underperformed by 15.18% the S&P500.

Investors sentiment decreased to 1.72 in Q3 2017. Its down 0.80, from 2.52 in 2017Q2. It worsened, as 12 investors sold Aratana Therapeutics, Inc. shares while 13 reduced holdings. 9 funds opened positions while 34 raised stakes. 31.53 million shares or 1.39% more from 31.10 million shares in 2017Q2 were reported. Pdt Partners holds 0.03% or 127,800 shares in its portfolio. State Street holds 597,904 shares. Alliancebernstein Lp owns 0% invested in Aratana Therapeutics, Inc. (NASDAQ:PETX) for 49,350 shares. Credit Suisse Ag has invested 0% in Aratana Therapeutics, Inc. (NASDAQ:PETX). Rathbone Brothers Pcl has invested 0.01% in Aratana Therapeutics, Inc. (NASDAQ:PETX). Strs Ohio holds 0% or 400 shares. 134,783 were reported by Bridgeway Cap Mngmt Inc. Royal Natl Bank Of Canada reported 4,125 shares stake. 1,000 are owned by North Star Mngmt Corp. National Bank Of Montreal Can reported 15,172 shares stake. Barclays Public Limited stated it has 1,491 shares. Rhumbline Advisers stated it has 0% in Aratana Therapeutics, Inc. (NASDAQ:PETX). Janney Montgomery Scott Ltd Liability owns 15,900 shares for 0% of their portfolio. Nationwide Fund Advisors invested in 78,383 shares or 0% of the stock. Geode Cap Mgmt Llc, a Massachusetts-based fund reported 291,972 shares.

Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. The company has market cap of $183.73 million. The Company’s product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. It currently has negative earnings. The firm markets GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE for appetite stimulation in dogs; and NOCITA, a post-operative anesthetic for cranial cruciate ligament surgery in dogs.

Since September 15, 2017, it had 0 insider purchases, and 5 insider sales for $686,083 activity. Standridge Brent had sold 10,000 shares worth $61,127. $158,040 worth of Aratana Therapeutics, Inc. (NASDAQ:PETX) was sold by TOOMAN CRAIG A on Thursday, January 11. On Friday, September 15 HEINEN ERNST sold $62,500 worth of Aratana Therapeutics, Inc. (NASDAQ:PETX) or 10,000 shares. St Peter Steven sold $92,301 worth of Aratana Therapeutics, Inc. (NASDAQ:PETX) on Tuesday, January 30.

Lazard Ltd, together with its subsidiaries, operates as a financial advisory and asset management firm worldwide. The company has market cap of $7.22 billion. The Company’s Financial Advisory segment offers various financial advisory services regarding mergers and acquisitions and other strategic matters, restructurings, capital structure, capital raising, corporate preparedness, and various other financial matters. It has a 29.12 P/E ratio. This segment serves corporate, partnership, institutional, government, sovereign, and individual clients.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>